FDA Approves Third Pegfilgrastim Biosimilar, LA-EP2006

The FDA approved a biosimilar to pegfilgrastim, called LA-EP2006 to decrease the incidence of infection, exhibited from febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer therapy that is associated with a clinically significant incidence of febrile neutropenia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news